Arbutus Biopharma Corporation ABUS Change in fair value of contingent consideration
Change in fair value of contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's change in fair value of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's change in fair value of contingent consideration?
- Arbutus Biopharma Corporation (ABUS) reported change in fair value of contingent consideration of $209K in Q1 2026.
- How has Arbutus Biopharma Corporation's change in fair value of contingent consideration changed year-over-year?
- Arbutus Biopharma Corporation's change in fair value of contingent consideration decreased by 30.1% year-over-year, from $299K to $209K.
- What is the long-term trend for Arbutus Biopharma Corporation's change in fair value of contingent consideration?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's change in fair value of contingent consideration has grown at a -0.6% compound annual growth rate (CAGR), from $1.87M to -$1.83M.
- What does change in fair value of contingent consideration mean?
- This represents the non-cash adjustment to the estimated fair value of liabilities related to acquisition-based earn-outs or contingent payments. Fluctuations in this value reflect changes in the probability or timing of achieving specific clinical or commercial milestones. It is a critical indicator of potential future cash outflows tied to past business combinations.